| Affected Systems |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
behavior/neurological
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
|
pup cannibalization
|
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
seizures
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
cardiovascular system
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
pulmonary vascular congestion
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
digestive/alimentary system
|
|
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
exocrine pancreas hypoplasia
|
|
|
|
|
√
|
|
√
|
|
|
|
|
|
|
embryo
|
|
|
|
|
|
|
|
√
|
|
√
|
|
|
|
|
abnormal mesendoderm development
|
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
abnormal decidualization
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
endocrine/exocrine glands
|
|
√
|
|
|
√
|
N
|
√
|
√
|
|
|
|
√
|
|
|
endocrine/exocrine gland phenotype
|
|
|
|
|
|
N
|
|
|
|
|
|
|
|
|
abnormal endometrial gland development
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
decreased endometrial gland number
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
abnormal pancreas morphology
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
decreased pancreatic alpha cell number
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
|
abnormal pancreatic beta cell morphology
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
decreased pancreatic beta cell number
|
|
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
pancreatic islet hypoplasia
|
|
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
disorganized pancreatic islets
|
|
√
|
|
|
|
|
|
|
|
|
|
√
|
|
|
abnormal pancreas development
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
pancreas hypoplasia
|
|
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
exocrine pancreas hypoplasia
|
|
|
|
|
√
|
|
√
|
|
|
|
|
|
|
|
abnormal insulin secretion
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
growth/size/body
|
|
√
|
|
|
|
|
|
|
|
|
|
√
|
|
|
decreased body size
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
|
postnatal growth retardation
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
hematopoietic system
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
increased neutrophil cell number
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
increased macrophage cell number
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
homeostasis/metabolism
|
|
√
|
√
|
√
|
|
N
|
√
|
|
√
|
|
|
√
|
|
|
homeostasis/metabolism phenotype
|
|
|
|
|
|
N
|
|
|
|
|
|
|
|
|
abnormal insulin secretion
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
hypoglycemia
|
|
√
|
|
|
|
|
|
|
|
|
|
√
|
|
|
hyperglycemia
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
|
decreased circulating glucagon level
|
|
√
|
|
|
|
|
|
|
|
|
|
√
|
|
|
increased circulating insulin level
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
cyanosis
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
increased glycogen level
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
decreased incidence of tumors by chemical induction
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
increased incidence of tumors by chemical induction
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
immune system
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
N
|
|
immune system phenotype
|
|
|
|
|
|
|
|
|
|
|
|
|
N
|
|
increased neutrophil cell number
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
increased macrophage cell number
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
integument
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
|
decreased skin turgor
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
liver/biliary system
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
increased hepatocellular carcinoma incidence
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
mortality/aging
|
|
√
|
√
|
√
|
√
|
|
√
|
|
|
√
|
|
√
|
|
|
postnatal lethality, complete penetrance
|
|
√
|
|
|
√
|
|
√
|
|
|
|
|
√
|
|
|
neonatal lethality, incomplete penetrance
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
postnatal lethality, incomplete penetrance
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
embryonic lethality during organogenesis, complete penetrance
|
|
|
|
|
|
|
|
|
|
√
|
|
|
|
neoplasm
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
decreased incidence of tumors by chemical induction
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
increased incidence of tumors by chemical induction
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
increased hepatocellular carcinoma incidence
|
|
|
|
|
|
|
|
|
√
|
|
|
|
|
nervous system
|
|
√
|
|
|
|
|
|
|
|
√
|
|
|
|
|
seizures
|
|
√
|
|
|
|
|
|
|
|
|
|
|
|
|
abnormal forebrain morphology
|
|
|
|
|
|
|
|
|
|
√
|
|
|
|
reproductive system
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
abnormal decidualization
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
abnormal endometrial gland development
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
decreased endometrial gland number
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
abnormal embryo invasion
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
impaired embryo implantation
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
abnormal uterus physiology
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
reduced female fertility
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
|
decreased litter size
|
|
|
|
|
|
|
|
√
|
|
|
|
|
|
respiratory system
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
√
|
|
pulmonary vascular congestion
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
impaired lung alveolus development
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
abnormal lung saccule morphology
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
abnormal pulmonary alveolus epithelial cell morphology
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
absent type I pneumocytes
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
abnormal type II pneumocyte morphology
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
absent alveolar lamellar bodies
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
increased pulmonary alveolus wall thickness
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
atelectasis
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
dilated respiratory conducting tube
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
pulmonary hyaline membrane formation
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
increased respiratory mucosa goblet cell number
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
√
|
|
respiratory distress
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
abnormal respiratory mechanics
|
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
increased airway resistance
|
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
decreased lung compliance
|
|
|
|
|
|
|
|
|
|
|
|
|
√
|
|
abnormal surfactant composition
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
abnormal surfactant secretion
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
|
decreased surfactant secretion
|
|
|
√
|
√
|
|
|
|
|
|
|
|
|
|
normal phenotype
|
√
|
|
|
|
|
|
|
|
|
|
√
|
|
|
|
no abnormal phenotype detected
|
√
|
|
|
|
|
|
|
|
|
|
√
|
|
|
Analysis Tools
